Page 2275 - Williams Hematology ( PDFDrive )

2250 Part XII: Hemostasis and Thrombosis Chapter 131: The Antiphospholipid Syndrome 2251

264. Silver RM, Porter TF, van Leeuween I, et al: Anticardiolipin antibodies: Clinical conse- 293. Opatrny L, David M, Kahn SR, Shrier I, Rey E: Association between antiphospholipid
quences of “low titers.” Obstet Gynecol 87:494–500, 1996. antibodies and recurrent fetal loss in women without autoimmune disease: A metaanal-
265. Tuhrim S, Rand JH, Wu XX, et al: Elevated anticardiolipin antibody titer is a stroke risk ysis. J Rheumatol 33:2214–2221, 2006.
factor in a multiethnic population independent of isotype or degree of positivity. Stroke 294. Kitchens CS: Prolonged activated partial thromboplastin time of unknown etiology:
30:1561–1565, 1999. A prospective study of 100 consecutive cases referred for consultation. Am J Hematol
266. Brey RL, Stallworth CL, McGlasson DL, et al: Antiphospholipid antibodies and stroke 27:38–45, 1988.
in young women. Stroke 33:2396–2400, 2002. 295. Liu HW, Wong KL, Lin CK, et al: The reappraisal of dilute tissue thromboplastin inhi-
267. Merrill JT, Shen C, Gugnani M, et al: High prevalence of antiphospholipid antibodies in bition test in the diagnosis of lupus anticoagulant. Br J Haematol 72:229–234, 1989.
patients taking procainamide. J Rheumatol 24:1083–1088, 1997. 296. Forastiero RR, Cerrato GS, Carreras LO: Evaluation of recently described tests for
268. El-Rayes BF, Edelstein M: Unusual case of antiphospholipid antibody syndrome detection of the lupus anticoagulant. Thromb Haemost 72:728–733, 1994.
presenting with extensive cutaneous infarcts in a patient on long-term procainamide 297. Galli M, Barbui T: Prothrombin as cofactor for antiphospholipids. Lupus 7(Suppl 2):
therapy. Am J Hematol 72:154, 2003. S37–S40, 1998.
269. Karmochkine M, Piette JC, Mazoyer E, et al: Antiphospholipid antibodies: Cause of 298. Galli M, Finazzi G, Bevers EM, Barbui T: Kaolin clotting time and dilute Russell’s viper
thrombosis or an epiphenomenon? Presse Med 24:267–270, 1995. venom time distinguish between prothrombin-dependent and beta 2-glycoprotein
270. Delluc A, Rousseau A, Le GM, et al: Prevalence of antiphospholipid antibodies in psy- I-dependent antiphospholipid antibodies. Blood 86:617–623, 1995.
chiatric patients users and non-users of antipsychotics. Br J Haematol 164:272–279, 299. Lenzi R, Rand JH, Spiera H: Anticardiolipin antibodies in pregnant patients with
2014. systemic lupus erythematosus. N Engl J Med 314:1392–1393, 1986.
271. Amengual O, Atsumi T, Khamashta MA, et al: Specificity of ELISA for antibody to beta 300. Empson M, Lassere M, Craig J, Scott J: Prevention of recurrent miscarriage for women
2-glycoprotein I in patients with antiphospholipid syndrome. Br J Rheumatol 35:1239– with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev
1243, 1996. 2:CD002859, 2005.
272. Alarcon-Segovia D, Mestanza M, Cabiedes J, Cabral AR: The antiphospholipid/cofactor 301. Galli M, Barbui T: Antiphospholipid antibodies and pregnancy. Best Pract Res Clin
syndromes. II. A variant in patients with systemic lupus erythematosus with antibod- Haematol 16:211–225, 2003.
ies to beta 2-glycoprotein I but no antibodies detectable in standard antiphospholipid 302. Laskin CA, Spitzer KA, Clark CA, et al: Low molecular weight heparin and aspirin
assays. J Rheumatol 24:1545–1551, 1997. for recurrent pregnancy loss: Results from the randomized, controlled HepASA trial.
273. Cabral AR, Amigo MC, Cabiedes J, Alarcon-Segovia D: The antiphospholipid/cofactor J Rheumatol 36:279–287, 2009.
syndromes: A primary variant with antibodies to beta 2-glycoprotein-I but no antibod- 303. Cowchock S, Reece EA: Do low-risk pregnant women with antiphospholipid antibodies
ies detectable in standard antiphospholipid assays. Am J Med 101:472–481, 1996. need to be treated? Organizing Group of the Antiphospholipid Antibody Treatment
274. Sanmarco M, Soler C, Christides C, et al: Prevalence and clinical significance of IgG Trial. Am J Obstet Gynecol 176:1099–1100, 1997.
isotype anti-beta 2-glycoprotein I antibodies in antiphospholipid syndrome: A compar- 304. Cowchock S: Treatment of antiphospholipid syndrome in pregnancy. Lupus 7(Suppl 2):
ative study with anticardiolipin antibodies. J Lab Clin Med 129:499–506, 1997. S95–S97, 1998.
275. Day HM, Thiagarajan P, Ahn C, et al: Autoantibodies to beta2-glycoprotein I in sys- 305. Lim W, Crowther MA, Eikelboom JW: Management of antiphospholipid antibody
temic lupus erythematosus and primary antiphospholipid antibody syndrome: Clinical syndrome: A systematic review. JAMA 295:1050–1057, 2006.
correlations in comparison with other antiphospholipid antibody tests. J Rheumatol 306. Khamashta MA, Cuadrado MJ, Mujic F, et al: The management of thrombosis in the
25:667–674, 1998. antiphospholipid-antibody syndrome. N Engl J Med 332:993–997, 1995.
276. Reber G, Schousboe I, Tincani A, et al: Inter-laboratory variability of anti-beta2-glyco- 307. Levine SR, Brey RL, Tilley BC, et al: Antiphospholipid antibodies and subsequent
protein I measurement. A collaborative study in the frame of the European Forum on thrombo-occlusive events in patients with ischemic stroke. JAMA 291:576–584, 2004.
Antiphospholipid Antibodies Standardization Group. Thromb Haemost 88:66–73, 2002. 308. Moll S, Ortel TL: Monitoring warfarin therapy in patients with lupus anticoagulants.
277. Hoxha A, Ruffatti A, Pittoni M, et al: The clinical significance of autoantibodies directed Ann Intern Med 127:177–185, 1997.
against prothrombin in primary antiphospholipid syndrome. Clin Chim Acta 413:911– 309. Tripodi A, Chantarangkul V, Clerici M, et al: Laboratory control of oral anticoagulant
913, 2012. treatment by the INR system in patients with the antiphospholipid syndrome and lupus
278. Lopez LR, Dier KJ, Lopez D, et al: Anti-beta 2-glycoprotein I and antiphosphatidylser- anticoagulant. Results of a collaborative study involving nine commercial thromboplas-
ine antibodies are predictors of arterial thrombosis in patients with antiphospholipid tins. Br J Haematol 115:672–678, 2001.
syndrome. Am J Clin Pathol 121:142–149, 2004. 310. Crowl A, Schullo-Feulner A, Moon JY: A review of warfarin monitoring in antiphos-
279. Audrain MA, El-Kouri D, Hamidou MA, et al: Value of autoantibodies to beta(2)- pholipid syndrome and lupus anticoagulant. Ann Pharmacother 48:1479–1483, 2014.
glycoprotein 1 in the diagnosis of antiphospholipid syndrome. Rheumatology (Oxford) 311. Agnelli G, Becattini C, Franco L: New oral anticoagulants for the treatment of venous
41:550–553, 2002. thromboembolism. Best Pract Res Clin Haematol 26:151–161, 2013.
280. Sanfelippo MJ, Joshi A, Schwartz S, et al: Antibodies to phosphatidylserine/proth- 312. Schaefer JK, McBane RD, Black DF, et al: Failure of dabigatran and rivaroxaban to pre-
rombin complex in suspected antiphospholipid syndrome in the absence of antibodies vent thromboembolism in antiphospholipid syndrome: A case series of three patients.
to cardiolipin or beta-2-glycoprotein I. Lupus 22:1349–1352, 2013. Thromb Haemost 112: 947–950, 2014.
281. Sciascia S, Khamashta MA, Bertolaccini ML: New tests to detect antiphospholipid anti- 313. Win K, Rodgers GM: New oral anticoagulants may not be effective to prevent venous throm-
bodies: Antiprothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) boembolism in patients with antiphospholipid syndrome. Am J Hematol 89:1017, 2014.
antibodies. Curr Rheumatol Rep 16:415, 2014. 314. Camps GM, Guil M, Sanchez LJ, et al: Fibrinolytic treatment in primary antiphospho-
282. Berard M, Chantome R, Marcelli A, Boffa MC: Antiphosphatidylethanolamine anti- lipid syndrome. Lupus 5:627–629, 1996.
bodies as the only antiphospholipid antibodies. I. Association with thrombosis and 315. Julkunen H, Hedman C, Kauppi M: Thrombolysis for acute ischemic stroke in the
vascular cutaneous diseases. J Rheumatol 23:1369–1374, 1996. primary antiphospholipid syndrome. J Rheumatol 24:181–183, 1997.
283. Rauch J, Janoff AS: Antibodies against phospholipids other than cardiolipin: Potential 316. Ho YL, Chen MF, Wu CC, et al: Successful treatment of acute myocardial infarction by
roles for both phospholipid and protein. Lupus 5:498–502, 1996. thrombolytic therapy in a patient with primary antiphospholipid antibody syndrome.
284. Yetman DL, Kutteh WH: Antiphospholipid antibody panels and recurrent pregnancy Cardiology 87:354–357, 1996.
loss: Prevalence of anticardiolipin antibodies compared with other antiphospholipid 317. Wallace DJ: The use of chloroquine and hydroxychloroquine for non-infectious con-
antibodies. Fertil Steril 66:540–546, 1996. ditions other than rheumatoid arthritis or lupus: A critical review. Lupus 5(Suppl 1):
285. de Maistre E, Gobert B, Bene MC, et al: Comparative assessment of phospholipid-binding S59–S64, 1996.
antibodies indicates limited overlapping. J Clin Lab Anal 10:6–12, 1996. 318. Erkan D, Yazici Y, Peterson MG, Sammaritano L, Lockshin MD: A cross-sectional study
286. Branch DW, Silver R, Pierangeli S, et al: Antiphospholipid antibodies other than lupus of clinical thrombotic risk factors and preventive treatments in antiphospholipid syn-
anticoagulant and anticardiolipin antibodies in women with recurrent pregnancy loss, drome. Rheumatology (Oxford) 41:924–929, 2002.
fertile controls, and antiphospholipid syndrome. Obstet Gynecol 89:549–555, 1997. 319. Tektonidou MG, Laskari K, Panagiotakos DB, Moutsopoulos HM: Risk factors for
287. Staub HL, Bertolaccini ML, Khamashta MA: Anti-phosphatidylethanolamine antibody, thrombosis and primary thrombosis prevention in patients with systemic lupus erythe-
thromboembolic events and the antiphospholipid syndrome. Autoimmun Rev 12:230– matosus with or without antiphospholipid antibodies. Arthritis Rheum 61:29–36, 2009.
234, 2012. 320. Petri M: Thrombosis and systemic lupus erythematosus: The Hopkins Lupus Cohort
288. Shapiro SS: The lupus anticoagulant/antiphospholipid syndrome. Annu Rev Med perspective. Scand J Rheumatol 25:191–193, 1996.
47:533–553, 1996. 321. Kaiser R, Cleveland CM, Criswell LA: Risk and protective factors for thrombosis in
289. Triplett DA: Antiphospholipid-protein antibodies: Clinical use of laboratory test results systemic lupus erythematosus: Results from a large, multi-ethnic cohort. Ann Rheum
(identification, predictive value, treatment). Haemostasis 26 Suppl 4:358–367, 1996. Dis 68:238–241, 2009.
290. Nojima J, Suehisa E, Akita N, et al: Risk of arterial thrombosis in patients with anticar- 322. Edwards MH, Pierangeli S, Liu X, et al: Hydroxychloroquine reverses thrombogenic
diolipin antibodies and lupus anticoagulant. Br J Haematol 96:447–450, 1997. properties of antiphospholipid antibodies in mice. Circulation 96:4380–4384, 1997.
291. Lockshin MD, Kim M, Laskin CA, et al: Prediction of adverse pregnancy outcome by 323. Rand JH, Wu XX, Quinn AS, et al: Hydroxychloroquine directly reduces the binding
the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers.
antiphospholipid antibodies. Arthritis Rheum 64:2311–2318, 2012. Blood 112:1687–1695, 2008.
292. Somers E, Magder LS, Petri M: Antiphospholipid antibodies and incidence of venous 324. Rand JH, Wu XX, Quinn AS, et al: Hydroxychloroquine reverses a procoagulant mech-
thrombosis in a cohort of patients with systemic lupus erythematosus. J Rheumatol anism for antiphospholipid syndrome: Evidence for a novel effect for an old antimalar-
29:2531–2536, 2002. ial drug. Blood 115:2292–2299, 2010.

Kaushansky_chapter 131_p2233-2252.indd 2250 9/18/15 5:11 PM